NMP-7

NMP-7 is a drug which acts as both a non-selective agonist of the CB1 and CB2 cannabinoid receptors, and also as a blocker of T-type calcium channels, the target of anticonvulsant drugs such as ethosuximide. NMP-7 has an agonist EC50 of 96.9nM at CB1 and 10.5nM at CB2, and an IC50 of 1.84μM for blocking Cav3.2 T-type calcium channels. In animal studies it produces potent analgesic effects in a variety of different tests.[1]

NMP-7
Identifiers
IUPAC name
  • (9-pentylcarbazol-3-yl)-piperidin-1-ylmethanone
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC23H28N2O
Molar mass348.490 g·mol−1
3D model (JSmol)
SMILES
  • c3cccc1c3n(CCCCC)c(cc2)c1cc2C(=O)N4CCCCC4
InChI
  • InChI=1S/C23H28N2O/c1-2-3-7-16-25-21-11-6-5-10-19(21)20-17-18(12-13-22(20)25)23(26)24-14-8-4-9-15-24/h5-6,10-13,17H,2-4,7-9,14-16H2,1H3
  • Key:NZEVKZAEMSMLMC-UHFFFAOYSA-N

See also

References
  1. You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P (November 2011). "Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands". Molecular Pain. 7: 1744-8069–7-89. doi:10.1186/1744-8069-7-89. PMC 3250956. PMID 22093952.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.